Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
The study published in NEJM entitled, “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors,” highlighted the antitumor activity of rezatapopt in heavily pretreated patients ...
Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil. The prevalence of fibroadenoma-like areas in malignant phyllodes tumors of the ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...
While the genes involved can differ, this example illustrates how most cancers arise. Accumulated DNA mutations, acquired either over time (ageing naturally leads to some DNA mistakes) or from ...
Researchers discover that people share the same cancer-causing mutations as felines ...
Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.Patients who ...
At the annual conference of the European Society of Human Genetics in Milan, biologist Dr. Edwige Kasper from the University Hospital of Rouen presented a case involving a sperm donor who unknowingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results